APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson's disease.

Autor: Okubadejo NU; Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria. nokubadejo@unilag.edu.ng.; Neurology Unit, Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria. nokubadejo@unilag.edu.ng., Okunoye O; Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK., Ojo OO; Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria.; Neurology Unit, Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria., Arabambi B; School of Population and Public Health, The University of British Columbia, Vancouver, BC, Canada., Akinyemi RO; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria., Osaigbovo GO; Jos University Teaching Hospital, Jos, Plateau State, Nigeria., Abubakar SA; Department of Medicine, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria., Iwuozo EU; Neurology Unit, Benue State University & Benue State University Teaching Hospital, Makurdi, Benue State, Nigeria., Wahab KW; Department of Medicine, University of Ilorin & University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria., Agabi OP; Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria.; Neurology Unit, Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria., Agulanna U; Neurology Unit, Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria., Imarhiagbe FA; University of Benin & University of Benin Teaching Hospital, Benin City, Edo State, Nigeria., Abiodun OV; General Hospital, Isolo, Lagos State, Nigeria., Achoru CO; Jos University Teaching Hospital, Jos, Plateau State, Nigeria., Adebowale AA; Neurology Unit, Department of Medicine, Obafemi Awolowo University & Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria., Adeniji O; Federal Medical Center, Abeokuta, Ogun State, Nigeria., Akpekpe JE; Federal Medical Center, Asaba, Delta State, Nigeria., Ali MW; Federal Teaching Hospital, Gombe, Gombe State, Nigeria., Ani-Osheku I; Asokoro District Hospital, Asokoro, Abuja, Federal Capital Territory, Nigeria., Arigbodi O; Department of Internal Medicine, Delta State University Teaching Hospital, Oghara, Delta State, Nigeria., Balarabe SA; Department of Medicine, College of Health Sciences, Usmanu Danfodiyo University & Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria., Bello AH; Department of Medicine, University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria., Ekenze OS; Neurology Unit, Department of Medicine, Faculty of Medical Sciences, University of Nigeria & University of Nigeria Teaching Hospital, Ituku Ozalla, Enugu State, Nigeria., Erameh CO; Irrua Specialist Hospital, Irrua, Edo State, Nigeria., Farombi TH; Chief Tony Anenih Geriatrics Center, University College Hospital, Ibadan, Oyo State, Nigeria., Fawale MB; Neurology Unit, Department of Medicine, Obafemi Awolowo University & Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria., Komolafe MA; Neurology Unit, Department of Medicine, Obafemi Awolowo University & Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria., Nwani PO; Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria., Nwazor EO; Department of Medicine, Madonna University College of Medical Sciences, Elele, Rivers State & Federal Medical Center, Owerri, Imo State, Nigeria., Nyandaiti Y; University of Maiduguri & University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria., Obehighe EE; Federal Medical Center, Keffi, Nassarawa State, Nigeria., Obiabo YO; Department of Internal Medicine, Delta State University & Delta State University Teaching Hospital, Oghara, Delta State, Nigeria., Odeniyi OA; General Hospital, Lagos Island, Lagos, Lagos State, Nigeria., Odiase FE; University of Benin & University of Benin Teaching Hospital, Benin City, Edo State, Nigeria., Ojini FI; Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria.; Neurology Unit, Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria., Onwuegbuzie GA; University of Abuja & University of Abuja Teaching Hospital, Gwagwalada, Abuja, Federal Capital Territory, Nigeria., Osemwegie N; University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria., Oshinaike OO; Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, Lagos State University College of Medicine, Ikeja, Lagos State, Nigeria., Otubogun FM; Federal Medical Center, Ebute-Metta, Lagos State, Nigeria., Oyakhire SI; Department of Internal Medicine, National Hospital, Abuja, Federal Capital Territory, Nigeria., Taiwo FT; Department of Medicine, University College Hospital, Ibadan, Oyo State, Nigeria., Williams UE; Department of Internal Medicine, University of Calabar/University of Calabar Teaching Hospital, Calabar, Cross Rivers State, Nigeria., Ozomma S; Department of Internal Medicine, University of Calabar/University of Calabar Teaching Hospital, Calabar, Cross Rivers State, Nigeria., Zubair Y; Department of Internal Medicine, National Hospital, Abuja, Federal Capital Territory, Nigeria., Hernandez D; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA., Bandres-Ciga S; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.; Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, MD, USA., Blauwendraat C; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.; Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, MD, USA., Singleton A; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.; Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, MD, USA., Houlden H; Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.; Neurogenetics Laboratory, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK., Hardy J; Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK., Rizig M; Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK.
Jazyk: angličtina
Zdroj: NPJ Parkinson's disease [NPJ Parkinsons Dis] 2022 Nov 12; Vol. 8 (1), pp. 155. Date of Electronic Publication: 2022 Nov 12.
DOI: 10.1038/s41531-022-00411-x
Abstrakt: The relationship between APOE polymorphisms and Parkinson's disease (PD) in black Africans has not been previously investigated. We evaluated the association between APOE polymorphic variability and self-declared cognition in 1100 Nigerians with PD and 1097 age-matched healthy controls. Cognition in PD was assessed using the single item cognition question (item 1.1) of the MDS-UPDRS. APOE genotype and allele frequencies did not differ between PD and controls (p > 0.05). No allelic or genotypic association was observed between APOE and age at onset of PD. In PD, APOE ε4/ε4 conferred a two-fold risk of cognitive impairment compared to one or no ε4 (HR: 2.09 (95% CI: 1.13-3.89; p = 0.02)), while APOE ε2 was associated with modest protection against cognitive impairment (HR: 0.41 (95% CI 0.19-0.99, p = 0.02)). Of 773 PD with motor phenotype and APOE characterized, tremor-dominant (TD) phenotype predominated significantly in ε2 carriers (87/135, 64.4%) compared to 22.2% in persons with postural instability/gait difficulty (PIGD) (30/135) and 13.3% in indeterminate (ID) (18/135, 13.3%) (p = 0.037). Although the frequency of the TD phenotype was highest in homozygous ε2 carriers (85.7%), the distribution of motor phenotypes across the six genotypes did not differ significantly (p = 0.18). Altogether, our findings support previous studies in other ethnicities, implying a role for APOE ε4 and ε2 as risk and protective factors, respectively, for cognitive impairment in PD.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: